Lymphoma clinical trials in Maryland
21 studies for Lymphoma are looking for participants at sites in Maryland.
Cities in Maryland
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 and older · All sexes · Updated Sep 28, 2026 · NCT01441089Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT00006518Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT03258567A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Maryland Oncology Hematology, Silver Spring
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Bethesda
RecruitingPhase 3
Ages 18 to 18 · All sexes · Updated Sep 8, 2026 · NCT07509151Sample Collection and Tracking for the Developmental Therapeutics Clinic
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 8, 2026 · NCT03269578Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
- Walter Reed National Military Medical Center, Bethesda
RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 3, 2026 · NCT07652580Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 5 and older · All sexes · Updated Aug 31, 2026 · NCT05237986Vaccine Responses in Patients With B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 4
Ages 18 to 90 · All sexes · Updated Aug 4, 2026 · NCT05170399CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 3 to 39 · All sexes · Updated Jul 30, 2026 · NCT05442515DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05663502Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated May 27, 2026 · NCT06856226Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.